CL2018002467A1 - El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint - Google Patents

El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint

Info

Publication number
CL2018002467A1
CL2018002467A1 CL2018002467A CL2018002467A CL2018002467A1 CL 2018002467 A1 CL2018002467 A1 CL 2018002467A1 CL 2018002467 A CL2018002467 A CL 2018002467A CL 2018002467 A CL2018002467 A CL 2018002467A CL 2018002467 A1 CL2018002467 A1 CL 2018002467A1
Authority
CL
Chile
Prior art keywords
potentiate
glucocorticoid receptor
receptor modulators
checkpoint inhibitors
checkpoint inhibitor
Prior art date
Application number
CL2018002467A
Other languages
English (en)
Inventor
Hazel Hunt
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CL2018002467A1 publication Critical patent/CL2018002467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO QUE COMBINA UN INHIBIDOR DE CHECKPOINT Y UN MODULADOR DEL RECEPTOR DE GLUCOCORTICOIDES PARA TRATAR CÁNCER, POR EJEMPLO, UN CÁNCER SENSIBLE A UN INHIBIDOR DE CHECKPOINT.
CL2018002467A 2016-03-01 2018-08-29 El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint CL2018002467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302106P 2016-03-01 2016-03-01
US201662320276P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
CL2018002467A1 true CL2018002467A1 (es) 2018-11-23

Family

ID=59744340

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002467A CL2018002467A1 (es) 2016-03-01 2018-08-29 El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint

Country Status (15)

Country Link
US (2) US10980797B2 (es)
EP (1) EP3423453A4 (es)
JP (3) JP6847120B2 (es)
KR (1) KR20180116372A (es)
CN (1) CN109071537B (es)
AU (1) AU2017228329B2 (es)
BR (1) BR112018067330A2 (es)
CA (1) CA3015218A1 (es)
CL (1) CL2018002467A1 (es)
IL (2) IL297201A (es)
MX (1) MX2018010564A (es)
PH (1) PH12018501848A1 (es)
SG (1) SG11201807421TA (es)
WO (1) WO2017151613A1 (es)
ZA (1) ZA201805787B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684612B2 (en) 2019-02-22 2023-06-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12097192B2 (en) 2023-05-09 2024-09-24 Corcept Therapeutics Incorpoarted Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
EP3600282A4 (en) 2017-03-31 2020-08-19 Corcept Therapeutics, Inc. GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF COLD CANCER
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP3858359B1 (en) 2018-09-28 2024-03-06 Kyungpook National University Industry-Academic Cooperation Foundation Composition, comprising a thiamine derivative, for prevention or treatment of hypercortisolemia
US10946005B2 (en) 2018-11-09 2021-03-16 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors
KR102657097B1 (ko) * 2018-12-19 2024-04-15 코어셉트 쎄라퓨틱스 인코포레이티드 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3158112A1 (en) * 2019-10-16 2021-04-22 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
WO2021154750A1 (en) * 2020-01-29 2021-08-05 Corcept Therapeutics Incorporated TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
CN115397418A (zh) * 2020-02-10 2022-11-25 科赛普特治疗学股份有限公司 使用选择性糖皮质激素受体调节剂刺激抗肿瘤反应的方法
CN115666573A (zh) 2020-05-27 2023-01-31 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c8底物的并行给药
CA3178771A1 (en) * 2020-05-27 2021-12-02 Hazel Hunt Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2023102569A1 (en) * 2021-12-03 2023-06-08 Board Of Regents, The University Of Texas System Glucocorticoid receptor blockade with mifepristone to sensitize pancreatic cancer to immunotherapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222421B2 (en) 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
MX2013010576A (es) * 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
KR102009007B1 (ko) 2011-10-04 2019-08-08 인비비스 파마슈티컬스 인코포레이티드 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
PL3338781T3 (pl) 2012-05-25 2020-03-31 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
US11413332B2 (en) * 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160299146A1 (en) 2013-11-20 2016-10-13 Dana-Farber Cancer Institute, Inc. Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
EP3848027B1 (en) 2013-11-25 2023-04-05 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
TWI736517B (zh) 2013-12-24 2021-08-21 美商必治妥美雅史谷比公司 作為抗癌劑之新穎三環化合物
US20150346210A1 (en) * 2014-05-30 2015-12-03 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
US20180064679A1 (en) * 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684612B2 (en) 2019-02-22 2023-06-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12097192B2 (en) 2023-05-09 2024-09-24 Corcept Therapeutics Incorpoarted Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Also Published As

Publication number Publication date
KR20180116372A (ko) 2018-10-24
IL261502B (en) 2022-11-01
SG11201807421TA (en) 2018-09-27
CN109071537B (zh) 2024-07-05
ZA201805787B (en) 2020-05-27
CN109071537A (zh) 2018-12-21
PH12018501848A1 (en) 2019-01-28
JP2019023228A (ja) 2019-02-14
US20210205294A1 (en) 2021-07-08
AU2017228329B2 (en) 2021-03-11
BR112018067330A2 (pt) 2019-01-22
US20190083486A1 (en) 2019-03-21
JP2019507159A (ja) 2019-03-14
MX2018010564A (es) 2018-11-09
US10980797B2 (en) 2021-04-20
WO2017151613A1 (en) 2017-09-08
CA3015218A1 (en) 2017-09-08
EP3423453A4 (en) 2019-11-06
IL261502B2 (en) 2023-03-01
JP2023060061A (ja) 2023-04-27
JP6847120B2 (ja) 2021-03-24
IL261502A (en) 2018-10-31
IL297201A (en) 2022-12-01
EP3423453A1 (en) 2019-01-09
AU2017228329A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CL2016000400A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112017024555A2 (pt) moduladores de ccr2
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
BR112019004123A2 (pt) sistemas e métodos para atuar dispositivos hidraulicamente atuados
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
CR20180089A (es) Compuestos útiles para inhibir a ror-gamma-t